Finance
TNFerade maker reports net loss of $5.6 million in first quarter
Published in Vaccine Weekly, May 26th, 2004
GenVec reported a net loss of $5.6 million compared to a net loss of $5.2 million in the comparable quarter of 2003.
The per share net loss of $0.11 decreased from $0.23 in the comparable quarter in 2003 and was primarily due to the issuance of new shares paid in consideration of the acquisition of Diacrin, Inc., in August 2003. GenVec ended the first quarter of 2004 with $33.7 million in cash and investments. As previously announced, GenVec raised an additional $12.6 million on April 16, 2004, through an offering of 4 million shares of common stock. Net...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2004-05-26)
More Articles from Vaccine Weekly
- Alzheimer Disease
Neuropathology of encephalitis after A-beta immunization described - Anthrax Vaccine
Glycine prevents thermal inactivation of Bacillus anthracis antigen - Cancer Vaccine
T-cell vaccine improved by antigen targeting via dendritic cells - Hepatitis C Virus
Relation of hepatitis C adaptation to disease progression reported - Meningococcal Vaccine
Cost-effectiveness of immunization strategies for meningitis published - AIDS/HIV Therapy
Lymphocytes in transgenic mice are resistant to viral infection - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
